PHCentral News is gathered daily to bring you the latest developments in pulmonary hypertension treatments and research as well as stories we think are useful on an array of topics. Under current news, you will find a dynamic list of stories for the last thirty (30) days. You will find older news stories in our archives. Stories about specific treatments can also be found in the medical section.
If you run across a PH news story we've missed or important story with broad appeal, please send us the link and we'll make sure it gets added. Send news: contact/info+phcentral+org.
- November 24, 2015
- Underrated value of repeated right heart catheterization in pulmonary hypertension with heart failure
(Journal of Thoracic Disease)
Left heart disease is accountable for about two thirds of pulmonary hypertension (PH) and PH in patients with congestive heart failure has negative impact on the survival (1). Pulmonary hypertension due to left heart disease (PH-LHD) is defined as a mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest and a pulmonary arterial wedge pressure (PAWP) >15 mmHg measured by right heart catheterization (RHC), which is essential for the evaluation of PH (2). A new clinical classification of PH-LHD was established on the 5th World Symposium on PH in Nice 2013 and was defined as isolated post-capillary PH (IpcPH) and combined post-capillary and precapillary PH (CpcPH) (3). CpcPH is hemodynamically defined as a mPAP >15 mmHg with a diastolic pressure difference (DPD = diastolic PAP – PAWP) ≥7 mmHg.
- November 23, 2015
- Catheter-Based Therapies for Patients with Medication-Refractory PAH
(Circulation: Cardiovascular Interventions)
Although there have been advances in pharmacotherapies for PAH, there are subsets of patients that are medication nonresponders or that continue to have a clinical decline despite maximal medical therapy. For those patients, there are several invasive strategies, such as atrial septostomy, a Potts shunt, and pulmonary artery denervation that have a therapeutic or palliative role in the management of PAH and are transitioning from surgical to catheter-based interventional procedures.
- November 22, 2015
- Pulmonary Artery Denervation Reduces Pulmonary Artery Pressure and Induces Histological Changes in an Acute Porcine Model of PH
(Circulation: Cardiovascular Interventions)
Pulmonary arterial hypertension is a devastating disease with high morbidity and mortality and limited treatment options. Recent studies have shown that pulmonary artery denervation improves pulmonary hemodynamics in an experimental model and in an early clinical trial. We aimed to evaluate the nerve distribution around the pulmonary artery, to determine the effect of radiofrequency pulmonary artery denervation on acute pulmonary hypertension induced by vasoconstriction, and to demonstrate denervation of the pulmonary artery at a histological level.
- Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With PAH of Different Causes: Phase II Results From the Pulmonary Artery Denervation-1 Study
(Circulation: Cardiovascular Interventions)
The mechanisms underlying pulmonary arterial hypertension (PAH) are multifactorial. The efficacy of pulmonary artery denervation (PADN) for idiopathic PAH treatment has been evaluated. This study aimed to analyze the hemodynamic, functional, and clinical responses to PADN in patients with PAH of different causes.
- November 21, 2015
- 3D MRI volumetry aids pulmonary hypertension diagnosis
"Currently, invasive right heart catheterization is required to confirm and often exclude diagnosis of pulmonary hypertension," study presenter Dr. Fabian Rengier, from University Hospital Heidelberg in Germany, told AuntMinnie.com. "Noninvasive imaging techniques, including 3D volumetry of pulmonary arteries, have the potential to exclude diagnosis of pulmonary hypertension in certain patients so that invasive right heart catheterization is not required in these patients."
- November 20, 2015
- Recorded Videos of Sessions 2015 SLHA Symposium On Pulmonary Hypertension
(Sri Lanka Heart Association)
Recorded video clips of the presentations and the inauguration ceremony of the Sri Lanka Annual Academic e Sessions of 2015, including the Symposium on Pulmonary Hypertension, are available for viewing.
- November 19, 2015
- Effect of Warfarin on Survival in Pulmonary Arterial Hypertension - See more at: http://www.acc.org/latest-in-cardiology/journal-scans/2015/11/04/15/48/effect-of-warfarin-treatment-on-survival-of-patients-with-pah?w_nav=LC#sthash.XrfPsmvZ.dpuf
(American College of Cardiology)
No significant survival advantage was observed in IPAH patients who started warfarin. In SSc-PAH patients, long-term warfarin was associated with poorer survival than inpatients not receiving warfarin, even after adjusting for confounders.
- November 18, 2015
- Test Your Knowledge: An Overview of PH and an Opportunity to Assess Your Hemodynamic Skills
(Cath Lab Digest)
Pulmonary hypertension (PHTN) is an abnormal elevation in pulmonary artery pressure and may be an idiopathic presentation, the result of left heart failure, pulmonary vascular disease, thromboembolic events, interstitial lung diseases, or a combination of these factors. PHTN is a hemodynamic and pathophysiological condition defined as an increase in mean pulmonary artery pressure greater than 25 mmHg at rest, as assessed by right heart catheterization. It is most commonly caused by left heart disease, particularly diastolic heart failure, and left-sided valvular disease. PHTN classified into one of 5 major groups and is generally a feature of advanced disease, regardless of the underlying causes, because it is often asymptomatic as it progresses. Because there are many potential causes of pulmonary hypertension, it is essential that the etiology underlying the pulmonary hypertension be clearly determined before embarking on treatment. In this regard, right heart catheterization plays a critical role.
- November 17, 2015
- Serum vasoactive intestinal peptide levels influence COPD exacerbation
Prior research has shown vasoactive intestinal peptide (VIP), the most abundant neuropeptide in the lung, is associated with pulmonary arterial hypertension and hypoxia. It also now seems that increased serum vasoactive intestinal peptide levels appear to be associated with acute exacerbation of chronic obstructive pulmonary disease, according to results of a nested cohort study.
- November 16, 2015
- IPF Experts Discuss Disease Diagnosis and Treatment at CHEST 2015
(Pulmonary Hypertension News)
The American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28 in Montreal, Canada, included a breakfast symposium where a panel of experts shared practical tips to help clinicians assess, diagnose, and manage idiopathic pulmonary fibrosis (IPF) and co-morbidities linked to the disease.
- November 15, 2015
- Eiger BioPharmaceuticals Announces Acquisition of Exclusive License to PAH Program from Stanford University
Eiger BioPharmaceuticals, Inc. today announced that it has acquired an exclusive license to technology for targeting effects of leukotriene B4 (LTB4) to modulate inflammation and immune response in the lung, providing a potential therapeutic approach for treating PAH. The technology was invented in the laboratory of Mark Nicolls, MD, Chief of Pulmonary and Critical Care Medicine at Stanford University.
- November 14, 2015
- New Policy Could Expand Access to Pediatric Lung Transplants
A policy change that allows broader geographic sharing of pediatric donor lungs could double the number of lung transplants in children in the United States, a new study finds.
- November 13, 2015
- phaware365 Mobile App Takes Pulmonary Hypertension Awareness Global, Social and High Tech
Leveraging novel research technologies and connectivity activations to create global engagement, phaware global association collaborates with industry leaders to raise awareness for pulmonary hypertension (PH), a rare, chronic lung disease that can lead to right heart failure.
- November 12, 2015
- Pulmonary Hypertension: First Guidelines Issued for Children
The first guidelines have been issued for diagnosing and treating children with pulmonary hypertension (PH), a sometimes-fatal heart and lung disease that affects 1.9 of every 1000 babies born each year.
- November 11, 2015
- Professor finds likely key to cure for pulmonary hypertension
(Yale Daily News)
According to a recent Yale co-authored study that was conducted at the Yale School of Medicine, research on smooth muscle cell progenitors could be the key to finding a cure for pulmonary hypertension.
- November 9, 2015
- SSc-PAH Outcomes Worse With Initial ERA
Time to clinical worsening was significantly faster with an endothelin receptor antagonist (ERA) as primary therapy for systemic sclerosis-related pulmonary arterial hypertension compared with a phosphodiesterase-5 (PDE5) inhibitor, or the combination of a PDE5 inhibitor and an ERA, researchers reported.
- November 8, 2015
- Pediatric PAH Gets First-Ever Management Guideline
Joint guidelines from the American Heart Association and American Thoracic Society, appearing in the journal Circulation, are now available to address the evaluation and treatment of pediatric pulmonary hypertension.
- November 7, 2015
- Yoga Program Matches Conventional COPD Rehab
A supervised yoga program proved as effective as conventional pulmonary rehabilitation for patients with stable chronic obstructive pulmonary disease (COPD), a small clinical trial showed.
- November 6, 2015
- ARB Therapy May Slow Emphysema Progression
A subset of patients with chronic obstructive pulmonary disease (COPD) with emphysema appeared to benefit from treatment with an angiotensin receptor blocker, supporting preclinical evidence of efficacy, a randomized clinical study suggested.
- November 5, 2015
- INOmax Granted Approved In Japan and Australia For Pulmonary Hypertension In Conjunction With Heart Surgery
(Lung Disease News)
INOmax is a vasodilator that improves ventilation/perfusion (V/Q) matching by reducing pulmonary vascular resistance (PVR).
In the US, INOmax cannot be for use in patients older than newborns, and the FDA has not approved its use in surgical settings.
- November 4, 2015
- Study Backs CellCept for ILD in Scleroderma
An immunosuppressive drug was as effective as a standard agent for interstitial lung disease (ILD) associated with scleroderma, a researcher said.
- November 3, 2015
- Reata’s Bardoxolone Methyl as PAH Therapy Shows Promise in Initial Phase 2 Data
Reata Pharmaceuticals, Inc. announced initial data from the LARIAT (A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension) trial (ClinicalTrials.gov Identifier: NCT02036970) evaluating bardoxolone methyl in pulmonary arterial hypertension (PAH) patients
In the LARIAT trial, efficacy analyses showed bardoxolone methyl increased 6MWD at doses of 2.5 to 10 mg through 16 weeks of treatment. Patients treated with bardoxolone methyl demonstrated a statistically significant mean increase in 6MWD compared to baseline of 22 meters and a placebo-corrected difference of 21.4 meters (p = 0.037).
- November 2, 2015
- Local Approach Cuts Mortality in Acute PE
Treating an acute pulmonary embolism with catheter-directed thrombolysis is safer but more expensive than systemic therapy, a researcher said.
- November 1, 2015
- IPF Registry Peels Back Curtain on Lung Disease
Most people with idiopathic pulmonary fibrosis have symptoms for more than a year before they are diagnosed, a researcher said here.
- October 31, 2015
- Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension
(BMC Pulmonary Medicine)
Schistosomiasis associated pulmonary arterial hypertension (Sch-PAH) might represent the most prevalent form of PAH worldwide. In Sch-PAH, the presence of aneurismal dilation of the pulmonary artery has been described, although it is still a matter of debate whether on average the pulmonary artery is more enlarged in Sc-PAH than IPAH.
- STOPBang Helps Predict OSA
An eight-item questionnaire might be used in the primary care setting to help identify patients who have obstructive sleep apnea (OSA), a researcher said.
- October 30, 2015
- Obesity-Related PAH: A Paradoxical Phenomenon
(Obesity News Today)
A phenomenon in the worlds of obesity and pulmonary arterial hypertension care is known as the “obesity paradox.” This paradox describes the apparent survival advantage high body mass index (BMI) seems to impart on patients with PAH. As reported by an article in the journal Chest, the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL Registry...
- Pulmonary hypertension in chronic obstructive pulmonary disease
Pulmonary hypertension (PH) is a common complication of advanced chronic obstructive pulmonary disease (COPD) and is defined by a mean pulmonary artery pressure (PAP) ≥ 25 mm Hg at rest in the supine position. Owing to its frequency, COPD is a common cause of PH; in fact, it is the second most frequent cause of PH, just after left heart diseases. PH is due to the elevation of pulmonary vascular resistance, which is caused by functional and morphological factors, chronic alveolar hypoxia being the most important. In COPD PH is generally mild to moderate, PAP usually ranging between 25 and 35 mm Hg in a stable state of the disease. A small proportion of COPD patients may present a severe or “disproportionate” PH with a resting PAP > 35–40 mm Hg. The prognosis is particularly poor in these patients. In COPD PH worsens during exercise, sleep and severe exacerbations of the disease, and these acute increases in afterload may favour the development of right heart failure.
- October 29, 2015
- Portable Ventilator Could Increase Physical Activity in Respiratory Conditions
It’s already well-known that greater activity translates to lower levels of mortality when it comes to chronic respiratory conditions. The latest data indicates that the Non-invasive Open Ventilation (NIOV) device be able to increase physical activity.
- Irish Researchers “Pull On Heart Strings” In World-First Study To Test Durability of Cardiac Tendons
AMBER (the Advanced Materials and BioEngineering Research Centre), the Science Foundation Ireland funded materials science centre based at Trinity College Dublin, has announced that Professor Bruce Murphy and Gillian Gunning are the first researchers in the world to "pull on heart strings" to measure the fatigue strength of chordae tendineae - cord-like tendons in the heart.
- October 28, 2015
- New guidelines for pediatric pulmonary hypertension
(Medical News Today)
very year, nearly 1 in 500 babies are born with pulmonary hypertension, a potentially fatal heart and lung disease. Now, the first ever guidelines for diagnosis and treatment have been published in the journal Circulation.
- Scientists discover new cell type behind pulmonary hypertension
(Medical News Today)
Scientists have discovered a new type of cell that is key to the development of pulmonary hypertension, and they believe it may lead to new targets for improved treatments.
- October 27, 2015
- Increased native T1-values at the interventricular insertion regions in precapillary pulmonary hypertension
(The International Journal of Cardiovascular Imaging)
Cardiac magnetic resonance imaging of the pressure overloaded right ventricle (RV) of precapillary pulmonary hypertension (PH) patients, exhibits late gadolinium enhancement at the interventricular insertion regions, a phenomenon which has been linked to focal fibrosis. Native T1-mapping is an alternative technique to characterize myocardium and has the advantage of not requiring the use of contrast agents. The aim of this study was to characterize the myocardium of idiopathic pulmonary arterial hypertension (IPAH), systemic scleroderma related PH (PAH-Ssc) and chronic thromboembolic PH (CTEPH) patients using native T1-mapping and to see whether native T1-values were related to disease severity.
- October 26, 2015
- Effects of Pulmonary Hypertension on Early Outcomes After Mitral Valve Replacement
(Pakistan Heart Journal)
Mitral valve replacement should be offered even in the presence of severe pulmonary hypertension, however these patients need extra postoperative care due to increased morbidity.